nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical Universitynefr-74Research ArticleПРОГРАММА НЕПРЕРЫВНОГО ПОСЛЕДИПЛОМНОГО ОБРАЗОВАНИЯ ПО НЕФРОЛОГИИPROGRAM ON CONTINUOUS POSTGRADUATE EDUCATION ON NEPHROLOGYКлинические рекомендации по диагностике и лечению диабетической нефропатииClinical practice guideline for diagnostics and treatment of diabetic nephropathyСмирновА. В.SmirnovA. V.noemail@neicon.ruДобронравовВ. А.DobronravovV. A.noemail@neicon.ruКисинаА. А.KisinaA. A.noemail@neicon.ruРумянцевА. Ш.RumyantsevA. Sh.noemail@neicon.ruКаюковИ. Г.KayukovI. G.noemail@neicon.ruНИИ нефрологии Первого Санкт-Петербургского государственного медицинского университета им. акад. И.П.ПавловаРоссияNephrology Research Institute Pavlov First Saint Petersburg State Medical UniversityRussian Federation2015010120151916777Copyright © Смирнов А.В., Добронравов В.А., Кисина А.А., Румянцев А.Ш., Каюков И.Г., 20152015Смирнов А.В., Добронравов В.А., Кисина А.А., Румянцев А.Ш., Каюков И.Г.Smirnov A.V., Dobronravov V.A., Kisina A.A., Rumyantsev A.S., Kayukov I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/74ReferencesShestakova M., Mukhin N.I. Dedov V. Titov et al. Protein-loading test, urinary albumin excretion and renal morphology in diagnosis of subclinical diabetic nephropathy. J. Int. Med., 1992; 231 (3): 213- 217Shestakova M., Mukhin N.I. Dedov V. Titov et al. Protein-loading test, urinary albumin excretion and renal morphology in diagnosis of subclinical diabetic nephropathy. J. Int. Med., 1992; 231 (3): 213- 217Горашко Н.М., Шестакова М.В., Чистяков Д.А. и соавт. Ассоциация полиморфных генов генов-кандидатов с диабетической нефропатией у больных сахарным диабетом 1 типа. Сахарный диабет 2002; (1): 38-44 [Gorashko N.M., Shestakova M.V., Chistiakov D.A. i soavt. Assotciatciia polimorfny'kh genov genov-kandidatov s diabeticheskoi' nefropatiei' u bol'ny'kh saharny'm diabetom 1 tipa. Saharny'i' diabet 2002; (1): 38-44]Горашко Н.М., Шестакова М.В., Чистяков Д.А. и соавт. Ассоциация полиморфных генов генов-кандидатов с диабетической нефропатией у больных сахарным диабетом 1 типа. Сахарный диабет 2002; (1): 38-44 [Gorashko N.M., Shestakova M.V., Chistiakov D.A. i soavt. Assotciatciia polimorfny'kh genov genov-kandidatov s diabeticheskoi' nefropatiei' u bol'ny'kh saharny'm diabetom 1 tipa. Saharny'i' diabet 2002; (1): 38-44]Шестакова М.В., Кошель Л.В., Вагодин В.А., Дедов И.И. Факторы риска прогрессирования диабетической нефропатии у больных с длительным течением сахарного диабета по данным ретроспективного анализа. Тер. архив 2006; (5): 60-64 [Shestakova M.V., Koshel' L.V., Vagodin V.A., Dedov I.I. Faktory' riska progressirovaniia diabeticheskoi' nefropatii u bol'ny'kh s dlitel'ny'm techeniem saharnogo diabeta po danny'm retrospetivnogo analiza. Ter. Arhiv 2006; (5): 60-64].Шестакова М.В., Кошель Л.В., Вагодин В.А., Дедов И.И. Факторы риска прогрессирования диабетической нефропатии у больных с длительным течением сахарного диабета по данным ретроспективного анализа. Тер. архив 2006; (5): 60-64 [Shestakova M.V., Koshel' L.V., Vagodin V.A., Dedov I.I. Faktory' riska progressirovaniia diabeticheskoi' nefropatii u bol'ny'kh s dlitel'ny'm techeniem saharnogo diabeta po danny'm retrospetivnogo analiza. Ter. Arhiv 2006; (5): 60-64].Тpофименко И.И., Добpонpавов В.А., Быстрова Н.Н. и др. Pаспpостpаненность снижения скоpости клубочковой фильтpации у больных сахаpным диабетом Тер. Архив. 2008; 6: 48-52 [Tpofimenko I.I., Dobponpavov V.A., By'stpova N.N. et al. Pasppostpanennost' snizheniia skoposti clubochkovoi' fil'tpatcii u bol'ny'kh sahapny'm diabetom Ter. Arhiv. 2008;6: 48-52]Тpофименко И.И., Добpонpавов В.А., Быстрова Н.Н. и др. Pаспpостpаненность снижения скоpости клубочковой фильтpации у больных сахаpным диабетом Тер. Архив. 2008; 6: 48-52 [Tpofimenko I.I., Dobponpavov V.A., By'stpova N.N. et al. Pasppostpanennost' snizheniia skoposti clubochkovoi' fil'tpatcii u bol'ny'kh sahapny'm diabetom Ter. Arhiv. 2008;6: 48-52]Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Eur Heart J. 2007; 28(1):88-136.Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Eur Heart J. 2007; 28(1):88-136.K/DOQI dinical Practice Guidelines and dinical Practice Recommendations for Diabetes and Chronic Kidney Disease Am J Kidney Dis 2007; 49: S1-S179.K/DOQI dinical Practice Guidelines and dinical Practice Recommendations for Diabetes and Chronic Kidney Disease Am J Kidney Dis 2007; 49: S1-S179.National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60 (5):850-886.National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60 (5):850-886.American Diabetes Association. Diabetes 2001 Vital Statistics. Alexandria, VA, ADA, 2001 9. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 2004; 27: (Suppl. 1): S15-S35,American Diabetes Association. Diabetes 2001 Vital Statistics. Alexandria, VA, ADA, 2001 9. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 2004; 27: (Suppl. 1): S15-S35,American Diabetes Association: Hypertension management in adults with diabetes (Position Statement). Diabetes Care 2004; 27 (Suppl. 1):S65-S67,American Diabetes Association: Hypertension management in adults with diabetes (Position Statement). Diabetes Care 2004; 27 (Suppl. 1):S65-S67,Bakris GL, Williams M, Dworkin L. et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kid Dis 2000; 36:646-661,Bakris GL, Williams M, Dworkin L. et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kid Dis 2000; 36:646-661,Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with typeBrenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with typediabetes and nephropathy. N Engl J Med 2001; 345:861-869,diabetes and nephropathy. N Engl J Med 2001; 345:861-869,DeFronzo RA: Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 1995; 3:510-564DeFronzo RA: Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 1995; 3:510-564Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329:977-986,Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329:977-986,Lewis EJ, Hunsicker LG, Clarke WR. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345:851-860,Lewis EJ, Hunsicker LG, Clarke WR. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345:851-860,Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462,Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462,Mogensen CE, Keane WF, Bennett PH. et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346:1080-1084,Mogensen CE, Keane WF, Bennett PH. et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346:1080-1084,Mogensen CE, Neldam S, Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 2000; 1440-1444,Mogensen CE, Neldam S, Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 2000; 1440-1444,Parving HH, Lehnert H, Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878,Parving HH, Lehnert H, Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878,UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing the risk of macrovascular complications in type 2 diabetes (UKPDS 39). BMJ 1998; 317:713-720,UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing the risk of macrovascular complications in type 2 diabetes (UKPDS 39). BMJ 1998; 317:713-720,UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853,UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853,UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998 317:703-713,UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998 317:703-713,Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention. Diabetologia. 1992; Sep;35(9):803-812Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention. Diabetologia. 1992; Sep;35(9):803-812Osterby R, Nyberg G, Karlberg I, Svalander C. Glomerular volume in kidneys transplanted into diabetic and non-diabetic patients. Diabet Med. 1992; Mar;9(2):144-149.Osterby R, Nyberg G, Karlberg I, Svalander C. Glomerular volume in kidneys transplanted into diabetic and non-diabetic patients. Diabet Med. 1992; Mar;9(2):144-149.Mauer SM, Bilous RW, Ellis E. et al. Some lessons from the studies of renal biopsies in patients with insulin-dependent diabetes mellitus. J Diabet Complications. 1988;2(4):197-202.Mauer SM, Bilous RW, Ellis E. et al. Some lessons from the studies of renal biopsies in patients with insulin-dependent diabetes mellitus. J Diabet Complications. 1988;2(4):197-202.Matsumae T, Jimi S, Uesugi N. et al. Clinical and morphometrical interrelationships in patients with overt nephropathy induced by non-insulin-dependent diabetes mellitus. A light- and electron-microscopy study. Nephron. 1999;81(1):41-48.Matsumae T, Jimi S, Uesugi N. et al. Clinical and morphometrical interrelationships in patients with overt nephropathy induced by non-insulin-dependent diabetes mellitus. A light- and electron-microscopy study. Nephron. 1999;81(1):41-48.Solini A, Dalla Vestra M, Saller A. et al. The angiotensinconverting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes. 2002;51(1):251-255.Solini A, Dalla Vestra M, Saller A. et al. The angiotensinconverting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes. 2002;51(1):251-255.Wirta OR, Pasternack AI, Mustonen JT. et al. Urinary albumin excretion rate and its determinants after 6 years in noninsulin-dependent diabetic patients. Nephrol Dial Transplant. 1996;11(3):449-456.Wirta OR, Pasternack AI, Mustonen JT. et al. Urinary albumin excretion rate and its determinants after 6 years in noninsulin-dependent diabetic patients. Nephrol Dial Transplant. 1996;11(3):449-456.Wirta O, Pasternack A, Laippala P, Turjanmaa V. Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clin Nephrol. 1996;45(1):10-17.Wirta O, Pasternack A, Laippala P, Turjanmaa V. Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clin Nephrol. 1996;45(1):10-17.Deferrari G, Repetto M, Calvi C. et al. Diabetic nephropathy: from micro- to macroalbuminuria. Nephrol Dial Transplant. 1998;13 Suppl 8:11-15.Deferrari G, Repetto M, Calvi C. et al. Diabetic nephropathy: from micro- to macroalbuminuria. Nephrol Dial Transplant. 1998;13 Suppl 8:11-15.Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7(1):35-43.Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7(1):35-43.Klausen KP, Parving HH, Scharling H, Jensen JS. The association betweenmetabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med. 2007;262(4):470-478.Klausen KP, Parving HH, Scharling H, Jensen JS. The association betweenmetabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med. 2007;262(4):470-478.Klausen KP, Scharling H, Jensen G, Jensen JS. New definition ofmicroalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension. 2005 Jul;46(1):33-37.Klausen KP, Scharling H, Jensen G, Jensen JS. New definition ofmicroalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension. 2005 Jul;46(1):33-37.Klausen K, Borch-Johnsen K, Feldt-Rasmussen B. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32-35.Klausen K, Borch-Johnsen K, Feldt-Rasmussen B. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32-35.Gall MA. Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences. Dan Med Bull. 1997 Nov;44(5):465-485. Review. PubMed PMID: 9408734.Gall MA. Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences. Dan Med Bull. 1997 Nov;44(5):465-485. Review. PubMed PMID: 9408734.Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783-788.Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783-788.Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996;156(3):286-289.Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996;156(3):286-289.Eknoyan G, Hostetter T, Bakris GL. et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42(4):617-622.Eknoyan G, Hostetter T, Bakris GL. et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42(4):617-622.Mogensen CE, Keane WF, Bennett PH. et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346(8982):1080-1084.Mogensen CE, Keane WF, Bennett PH. et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346(8982):1080-1084.Pedrini MT, Levey AS, Lau J. et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124(7):627-632.Pedrini MT, Levey AS, Lau J. et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124(7):627-632.Gross JL, Zelmanovitz T, Moulin CC. et al. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial. Diabetes Care. 2002;25(4):645-651.Gross JL, Zelmanovitz T, Moulin CC. et al. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial. Diabetes Care. 2002;25(4):645-651.Diabetes Control and Complications Trial/Epidemiology of Diabetes interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).Arch Intern Med. 2009;169(14):1307-1316.Diabetes Control and Complications Trial/Epidemiology of Diabetes interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).Arch Intern Med. 2009;169(14):1307-1316.Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159-2167Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159-2167Delahanty LM, Halford BN. The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care. 1993;16(11):1453-1458.Delahanty LM, Halford BN. The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care. 1993;16(11):1453-1458.Anderson EJ, Richardson M, Castle G. et al. Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc. 1993;93(7):768-772.Anderson EJ, Richardson M, Castle G. et al. Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc. 1993;93(7):768-772.Watkins P. The UKPDS. A model for gathering the evidence for the management of chronic diseases. UK Prospective Diabetes Study Group. J R Coll Physicians Lond. 1998;32(6):510-511.Watkins P. The UKPDS. A model for gathering the evidence for the management of chronic diseases. UK Prospective Diabetes Study Group. J R Coll Physicians Lond. 1998;32(6):510-511.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998;352(9139):1558.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998;352(9139):1558.Intensive blood-glucose control with sulphonyl urea’s or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999;354(9178):602.Intensive blood-glucose control with sulphonyl urea’s or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999;354(9178):602.Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):720-726Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):720-726Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):713-720.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):713-720.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12;317(7160):703-13. Erratum in: BMJ 1999;318(7175):29.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998 Sep 12;317(7160):703-13. Erratum in: BMJ 1999;318(7175):29.Manley S. Haemoglobin A1c - a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med.2003; 41(9):1182-1190.Manley S. Haemoglobin A1c - a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med.2003; 41(9):1182-1190.Vandenhaute V. Palliative care and type II diabetes: A need for new guidelines? Am J Hosp Palliat Care. 2010;27(7):444-445.Vandenhaute V. Palliative care and type II diabetes: A need for new guidelines? Am J Hosp Palliat Care. 2010;27(7):444-445.Schwartz V. [Critical notes on the results of studies (ACCORD, ADVANCE, VADT)of the efficiency of intensive therapy of type 2 diabetes mellitus]. Klin Med(Mosk). 2011;89(3):18-20. Review. Russian.Schwartz V. [Critical notes on the results of studies (ACCORD, ADVANCE, VADT)of the efficiency of intensive therapy of type 2 diabetes mellitus]. Klin Med(Mosk). 2011;89(3):18-20. Review. Russian.Chalmers J, Joshi R, Kengne AP, MacMahon S. Blood pressure lowering withfixed combination perindopril-indapamide: key findings from ADVANCE. J Hypertens Suppl. 2008;26(2):S11-15.Chalmers J, Joshi R, Kengne AP, MacMahon S. Blood pressure lowering withfixed combination perindopril-indapamide: key findings from ADVANCE. J Hypertens Suppl. 2008;26(2):S11-15.ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S,Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcmes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S,Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcmes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect ofangiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456-1462. Erratum in:N Engl J Med 1993;330(2):152.Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect ofangiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456-1462. Erratum in:N Engl J Med 1993;330(2):152.Laffel LM, McGill JB, Gans DJ. The beneficial effect ofangiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995 ;99(5):497-504.Laffel LM, McGill JB, Gans DJ. The beneficial effect ofangiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995 ;99(5):497-504.Brenner BM, Cooper ME, de Zeeuw D. et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.Brenner BM, Cooper ME, de Zeeuw D. et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.Mogensen CE. Diabetic nephropathy: evidence for renoprotection and practice. Heart. 2000 ;84 Suppl 1:i26-28Mogensen CE. Diabetic nephropathy: evidence for renoprotection and practice. Heart. 2000 ;84 Suppl 1:i26-28Mogensen CE. ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. J Renin Angiotensin Aldosterone Syst. 2000;1(3):234-239.Mogensen CE. ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. J Renin Angiotensin Aldosterone Syst. 2000;1(3):234-239.Mogensen CE, Neldam S, Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.Mogensen CE, Neldam S, Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.Fried LF, Forrest KY, Ellis D. et al. Lipidmodulation in insulindependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications. 2001;15(3):113-119.Fried LF, Forrest KY, Ellis D. et al. Lipidmodulation in insulindependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications. 2001;15(3):113-119.Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on theprogression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260-269.Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on theprogression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260-269.Collins R, Armitage J, Parish S. et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.Collins R, Armitage J, Parish S. et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.Predictors of the development of microalbuminuria in patients with Type I diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group. Diabet Med. 1999;16(11):918-925.Predictors of the development of microalbuminuria in patients with Type I diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group. Diabet Med. 1999;16(11):918-925.Gall MA, Hougaard P, Borch-Johnsen K. et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783-788.Gall MA, Hougaard P, Borch-Johnsen K. et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783-788.Gerstein HC, Mann JF, Yi Q, Zinman B. et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-426.Gerstein HC, Mann JF, Yi Q, Zinman B. et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-426.Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304-349.Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304-349.Bakris GL et al. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998;11(10):158S-162S.Bakris GL et al. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998;11(10):158S-162S.
The authors declare that there are no conflicts of interest present.